Authors : Achal Mohan Deogade; Payal Jitin Yadav

Volume/Issue : Volume 11 - 2026, Issue 1 - January

Google Scholar : https://tinyurl.com/4bkeyvdp

Scribd : https://tinyurl.com/3baez9an

DOI : https://doi.org/10.38124/ijisrt/26jan495

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Abstract : Chronic Obstructive Pulmonary Disease (COPD) is a progressive, non-communicable respiratory condition marked by persistent airflow limitation, chronic inflammation, oxidative stress, mucus hypersecretion, and mitochondrial dysfunction induced by hypoxia. Although advancements have been made in conventional pharmacotherapy, current treatments mainly offer symptomatic relief and do not sufficiently alter disease progression. This has led to increasing interest in complementary and plant-based therapies. Adhatoda vasica (Justicia adhatoda), commonly referred to as Vasaka, is a well-regarded medicinal plant in Ayurvedic and Unani medicine, traditionally utilized for treating asthma, bronchitis, cough, and other respiratory issues. This review critically examines the therapeutic potential of A. vasica in managing COPD by synthesizing findings from recent phytochemical, pharmacological, preclinical, and emerging clinical studies. The plant is abundant in bioactive compounds, especially quinazoline alkaloids (such as vasicine and vasicinone), flavonoids, phenolic acids, phytosterols, saponins, and tannins. Collectively, these constituents demonstrate bronchodilatory, mucolytic, anti- inflammatory, antioxidant, antimicrobial, and anti-hypoxic properties. Experimental research indicates that A. vasica modulates essential inflammatory pathways, mitigates oxidative damage, enhances mucus clearance, protects mitochondrial function via Nrf2 and HIF-1α signaling, and reduces airway remodeling—key pathological features of COPD. Recent advancements in formulation strategies, including standardized extracts and innovative pulmonary delivery systems, have further improved its therapeutic potential. Overall, Adhatoda vasica stands out as a promising multi-targeted herbal option for adjunctive COPD therapy. However, comprehensive clinical trials that are large-scale and well-structured, along with standardized phytochemical profiling and thorough safety and pharmacokinetic studies, are crucial to confirm its clinical efficacy and long-term therapeutic role in managing COPD.

References :

1. A COPD HANDBOOK "Breath the lung association"
2. Epidemiological trends and risk factors of chronic obstructive pulmonary disease in young individuals based on the 2021 global burden of disease data (1990–2021)
3. The history of COPD-International Journal of COPD 2006 Thomas L Petty University of Colorado Medical Center, Denver, CO, USA; Rush - Presbyterian-St Luke’s Medical Center, Chicago, Il, USA
4. Adeloye, D., et al. (2023). Global and regional estimates of COPD prevalence and mortality: A systematic review and meta-analysis. The Lancet Respiratory Medicine, 11(9), 803–815.
5. Salvi, S., & Barnes, P. J. (2023). Is exposure to biomass smoke the biggest risk factor for COPD globally? The Lancet Respiratory Medicine, 11(6), 495–497
6. India State-Level Disease Burden Initiative CRD Collaborators. (2022). The burden of chronic respiratory diseases and their risk factors in India, 1990–2019. The Lancet Global Health, 10(12), e1720–e1734.
7. Sundaram, B., et al. (2019). A small-molecule modulator rescues hypoxia-induced mitochondrial dysfunction in COPD models via Nrf2 activation. Cell Death & Disease, 10(12).
8. Kumar, S., & Sharma, M. (2021). Evaluation of Vasaka extract in cigarette smoke induced COPD models. International Journal of COPD, 16, 3157–3166.
9. Gilani, A.H., et al. (2007). Bronchodilator and calcium channel blocking activities of Adhatoda vasica. Journal of Ethnopharmacology, 111(3), 463–469.
10. Sharma, V., et al. (2014). Phytochemical and pharmacological profile of Adhatoda vasica: traditional uses to modern therapies. IJPSRR, 27(2), 364–372.
11. Naveed, M., et al. (2020). Pharmacological overview of Adhatoda vasica and its therapeutic potential in respiratory diseases. Biomedicine & Pharmacotherapy, 129, 110409.
12. Gupta, R., et al. (2018). Anti-inflammatory and antioxidant potential of Adhatoda vasica leaves in experimental chronic airway inflammation. JTCM, 8(3), 330–337.
13. [Rehmat Jahan*, Shoeb Ahmed Ansari, Asma Sattar Khan, Khadija Abdul Hafiz and Usha Devi. A review of phytoconstituent and therapeutic uses of JUSTICA ADHATODA A plant  of diverse medicinal properties used in unani system of medicine.]
14. C. N. Varsha, B. P. Meghana *, T.Balasubramanian, D.M. Sinchana and S. U. Tejas (2025)an updated review on phytochemical constituents andpharmacological activities of Adhatoda vasica (L). NEES
15.  [Semwal, R., Semwal, D. K., Mishra, S. P., & Semwal, R. (2022). Phytochemistry, pharmacology, and traditional uses of Adhatoda vasica: A comprehensive review. Plants, 11(3), 350.]
16. Patel, R. & Thakur, K., 2023, Annals of Phytomedicine, 12(1), 120–128.
    Sharma, P. et al., 2021, Journal of Herbal Medicine, 29, 100473.
17. Singh, A., & Yadav, D. (2022). Ethnopharmacological and therapeutic potential of Adhatoda vasica in respiratory disorders. Journal of Pharmacognosy and Phytochemistry, 11(1), 45–52.
18. Patel, R. & Thakur, K. (2023). Annals of Phytomedicine, 12(1), 120–128.
    Agustí, A. et al. (2023). Nature Medicine, 29, 169–182.]
19. Sharma, P. et al. (2021). Journal of Herbal Medicine, 29, 100473.
    Barnes, P. J. (2022). New England Journal of Medicine, 386, 1861–1873.
20. Kumar, S. et al. (2022). Journal of Ethnopharmacology, 298, 115623.
    Celli, B. R. et al. (2021). American Journal of Respiratory and Critical Care Medicine, 203(1), 24–36.]
21. [Choudhary, N. et al. (2023). Phytochemistry Reviews, 22, 987–1004.
    GOLD Scientific Committee. (2024). Global Initiative for Chronic Obstructive Lung Disease Report.
22. Barnes, P. J. (2022). New England Journal of Medicine, 386, 1861–1873.
23. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2023
24. GBD 2023 Chronic Respiratory Diseases Collaborators. (2024). Global burden of chronic obstructive pulmonary disease, 1990–2023. The Lancet, 403(10429), 1857–1874. https://doi.org/10.1016/S0140-6736(24)00232-1]
25. India State-Level Disease Burden Initiative CRD Collaborators. (2022). The burden of chronic respiratory diseases and their risk factors in India, 1990–2019. The Lancet Global Health, 10(12), e1720–e1734.
26. Kumar & Singh, 2022, Phytomedicine – Reported COX-2 and iNOS suppression in LPS-induced inflammation.
27. Bafna et al., 2023, Pharmacology Research & Perspectives – Demonstrated bronchodilation in guinea pig tracheal models.
28.  Sharma et al., 2022, Respiratory Physiology & Neurobiology – Showed PDE inhibition and improved airway patency.
29. Das & Banerjee, 2023, Journal of Natural Remedies – Reported strong ROS scavenging and improved antioxidant status.
30. Patel et al., 2022, Saudi Journal of Biological Sciences – Confirmed antioxidant protection in experimental COPD.
31. Singh et al., 2022, Cell Reports Medicine – Found that vasicine-containing extracts reduce HIF 1α activation.
32. Chandel et al., 2023, Frontiers in Pharmacology – Demonstrated mitochondrial protection in hypoxia-induced lung injury.
33. Joshi et al., 2023, Herbal Medicine Journal – Showed effective mucolytic activity.
34. Nair et al., 2022, Ayurvedic Pharmacology Review – Reported reduced mucin levels in airway models.
35.  Rao et al., 2023, BMC Complementary Medicine and Therapies – Demonstrated strong antibacterial activity.
36. Desai et al., 2022, Journal of Applied Microbiology – Confirmed antimicrobial potential against respiratory pathogens.
37.  Choudhary, R., et al. (2023).Phytochemical profiling and standardization of Adhatoda vasica leaf extract.
38. Patel, P., & Thakur, N. (2023) Formulation and evaluation of herbal tablets containing Adhatoda vasica extract. Journal of Herbal Medicine,
39. Sharma, S., et al. (2023) Vasicine-loaded polymeric nanoparticles for enhanced pulmonary delivery. Journal of Drug Delivery Science and Technology,
40. Snider GL. Chronic obstructive pulmonary disease. American Review of Respiratory Disease. 1989;140(3):S3–S8.
41. Sharma, S., et al. (2023) Vasicine-loaded polymeric nanoparticles for enhanced pulmonary delivery. Journal of Drug Delivery Science and Technology.